Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2011

Conditions
Bipolar Depression
Interventions
DRUG

Memantine

Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.

DRUG

Placebo

No active medication, only placebo

Trial Locations (1)

46202

Indiana University Adult Psychiatric Clinic, Indianapolis

All Listed Sponsors
lead

Indiana University School of Medicine

OTHER

NCT00305578 - Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression | Biotech Hunter | Biotech Hunter